The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

Nonalcoholic fatty liver disease (NAFLD) and its more severe form, nonalcoholic
steatohepatitis (NASH), represent a growing worldwide epidemic and a high unmet medical …

Metformin was first used to treat type 2 diabetes in the late 1950s and in 2022 remains the
first-choice drug used daily by approximately 150 million people. An accumulation of …

Health professionals are encouraged to take the Guidelines fully into account when
exercising their clinical judgment, as well as in the determination and the implementation of …

Background Three different glucagon-like peptide-1 (GLP-1) receptor agonists reduce
cardiovascular outcomes in people with type 2 diabetes at high cardiovascular risk with high …

Summary Each year, the American Heart Association (AHA), in conjunction with the National
Institutes of Health and other government agencies, brings together in a single document the …

Diabetes mellitus predisposes affected individuals to a significant spectrum of
cardiovascular complications, one of the most debilitating in terms of prognosis is heart …

The management of type 2 diabetes mellitus (T2DM) is becoming increasingly complex.
Sodium–glucose cotransporter type 2 inhibitors (SGLT2is) are the newest antidiabetic …

Abstract The American Diabetes Association and the European Association for the Study of
Diabetes convened a panel to update the prior position statements, published in 2012 and …

The prevalence of non-alcoholic fatty liver disease (NAFLD) is increasing worldwide. In
some patients with NAFLD, isolated steatosis can progress to advanced stages with non …